The results highlight the importance of evaluating and monitoring cognitive function in individuals with recent critical illness or major infections, especially if they are already at risk for dementia.
Results of a safety review have led to the discontinuation of phase 3 clinical studies of elenbecestat, an investigational oral BACE (beta amyloid cleaving enzyme) inhibitor, which was being assessed for early Alzheimer disease (AD) treatment.
A phase 3 trial evaluating pimavanserin (Acadia) for the treatment of dementia-related psychosis has been stopped early due to positive findings in a planned interim efficacy analysis.
Use of hearing aids is associated with lower risks for being diagnosed with Alzheimer disease, dementia, depression, anxiety, and injurious falls among elderly adults diagnosed with hearing loss.
Cerebrospinal fluid (CSF) α-synuclein decreases early in untreated Parkinson disease (PD), yet α-synuclein does not appear to correlate with disease progression. This is according to a study in Movement Disorders. The ongoing, longitudinal study (Parkinson’s Progression Markers Initiative) included newly diagnosed, untreated patients with PD (n=423; mean age, 61.7 years) as well as age- and…
The Food and Drug Administration (FDA) has approved Myobloc (rimabotulinumtoxinB injection; US WorldMeds) for the treatment of chronic sialorrhea in adults.
The Food and Drug Administration (FDA) has approved Nourianz (istradefylline; Kyowa Kirin) tablets as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson disease (PD) experiencing “off” episodes.
Inherited and noninherited genetic factors contribute equally to the risk for developing amyotrophic lateral sclerosis (ALS), and first-degree relatives of people with ALS tend to have a higher risk for the disease compared with the general population, even in the absence of known ALS-associated genetic mutations.
